BioSpace News Archive

Captor Therapeutics S.A., a biopharmaceutical company focused on the development of targeted protein degradation drugs for cancer and autoimmune diseases, announces that it has been invited to participate in the 8th Annual LSX World Congress, taking place in London from 10th to 11th May 2022.

MTL-STING is the second drug candidate to be advanced from the Company’s internal pipeline of small activating RNA therapeutics STING is a highly validated drug target that plays a key role in immune evasion in cancer MiNA Therapeutics Limited, the pioneer in small activating RNA therapeutics, presents preclinical proof of mechanism data on MTL‑STING as a novel cancer immunotherapy.

The shareholders of Spago Nanomedical AB, corporate registration number 556574-5048 are hereby summoned to the Annual General Meeting on Wednesday May 18, 2022, at 4.00 p.m. CEST in the premises of Advokatfirman Cederquist at Hovslagargatan 3 in Stockholm.

BioNTech SE presented data from its ongoing first-in-human Phase 1/2 trial evaluating the safety and preliminary efficacy of the Company’s novel CAR-T cell therapy candidate, BNT211, in patients with advanced solid tumors.

Royal Philips, a global leader in health technology, and Oulu University Hospital announced a strategic 10-year partnership agreement to support the hospital’s ambitious OYS2030 renewal program.

Diagnostics company SphingoTec GmbH announced the implementation of two critical care biomarkers to guide the application of a potential new drug candidate for the treatment of COVID-19 patients.

4TEEN4 pharmaceuticals GmbH announces that its biomarker DPP3 will be used in a biomarker-guided trial in severe COVID-19 as communicated by the University Hospital Hamburg-Eppendorf and SphingoTec GmbH.

InventisBio Co., Ltd., a clinical-stage biotech company based in Shanghai, China has published the clinical data of their oral KRAS G12C inhibitor D-1553, for the first time in cancer patients.

APRINOIA Therapeutics announces that the U.S. Food and Drug Administration has granted a may proceed authorization for its novel therapeutic anti-tau monoclonal antibody, APNmAb005, allowing the company to test and evaluate its safety in healthy subjects in a phase 1 single ascending dose study.

Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of novel immunotherapies for difficult to treat solid cancers announced positive preclinical data on the treatment and analysis of the checkpoint resistant pancreatic syngeneic murine tumor model, Pan02.